Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer

NCT06469957 | Completed

• 1 other identifier: CHRO-2023-12
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients (only questionnaires) with bronchopulmonary cancer treated by Chemotherapy and/or Immunotherapy or Oral targeted therapy. The primary objective of the study is to evaluate the number of unscheduled consultations/hospitalizations during 6 months.

Conditions

Patients With Bronchopulmonary Cancer

Keywords

Hospital pharmacist; Pharmaceutical intervention; Chemotherapy / Immunotherapy /oral targeted therapy; Bronchopulmonary cancer

Outcome Measures

Primary Outcomes (1)

• Impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations.

  Number of unscheduled consultations or hospitalizations during the follow up phase

  From enrolment to the end of the follow up phase (6 months)

Secondary Outcomes (6)

• Impact of hospital pharmacist (interview) on cancelled consultations/hospitalizations rate

  From enrolment to the end of the follow up phase (6 months)

• Impact of hospital pharmacist (interview) on treatment observance (number of dispensation)

  From enrolment to the end of the follow up phase (6 months)

• Impact of hospital pharmacist (interview) on treatment observance (gap between dispensation)

  From enrolment to the end of the follow up phase (6 months)

• Impact of hospital pharmacist (interview) on adverse effects

  From enrolment to the end of the follow up phase (6 months)

• Impact of hospital pharmacist (interview) on adverse effects leading to interrupted or withdrawn treatment

  From enrolment to the end of the follow up phase (6 months)

Interventions

Questionnaires and data collection sheet OTHER

Questionnaires

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with bronchopulmonary cancer who received a new treatment with oral targeted therapy, chemotherapy or immunotherapy.

You may qualify if:

• Male or female ≥ 18 years
• Patient without cognitive impairments
• Patient with bronchopulmonary cancer
• Patient treated by chemotherapy, immunotherapy or oral targeted therapy

You may not qualify if:

• Patient informed and opposed to participate
• Language barrier and lack of translator
• Patient under guardianship, curatorship or deprived of liberty
• Pregnant or breastfeeding women
• Participation in any drug clinical drug trials
• Patient with no insurance

Sponsors & Collaborators

• Centre Hospitalier Régional d'Orléans: lead

Study Sites (1)

CHU d'Orléans

Orléans, 45067, France

Location

Related Publications (1)

• Babin M, Folliard C, Robert J, Sorrieul J, Kieffer H, Augereau P, Devys C. [Pharmaceutical consultations in oncology: Implementation, one-year review and outlooks]. Ann Pharm Fr. 2019 Sep;77(5):426-434. doi: 10.1016/j.pharma.2019.05.001. Epub 2019 Jul 7. French.

  PMID: 31288930 BACKGROUND

MeSH Terms

Interventions

Surveys and Questionnaires

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Catherine DA VIOLANTE, Dr

  CHU d'Orléans

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 3, 2024
• First Posted: June 24, 2024
• Study Start: June 25, 2024
• Primary Completion: June 23, 2025
• Study Completion: December 31, 2025
• Last Updated: March 20, 2026

Record last verified: 2026-03

Locations

FR (1)